Optimal dosing regimen of biapenem based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation in patients with febrile neutropenia and haematological malignancies

•A population pharmacokinetic model was established in Chinese febrile neutropenic (FN) patients with haematologic malignancies.•Creatinine clearance and concomitant posaconazole were considered to be significant covariates affecting the clearance of biapenem.•Biapenem 300 mg every 12 h (0.5 h and 3 h infusion) may not achieve satisfactory clinical results with minimum inhibitory concentration >1 g/L.•Other antibacterial agents were more suitable for treatment of Pseudomonas aeruginosa and Acinetobacter baumannii infection.